Current address: Centre for Cancer Research, Mouse Cancer Genetics Program, National Cancer Institute Frederick, MD, USA.
Prognostic utility of autoantibodies to α-enolase and Hsp70 for cancer of the gingivo-buccal complex using immunoproteomics
Article first published online: 1 MAR 2013
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PROTEOMICS - Clinical Applications
Special Issue: Focus on Cancer Proteomics
Volume 7, Issue 5-6, pages 392–402, June 2013
How to Cite
Pranay, A., Shukla, S., Kannan, S., Malgundkar, S. A., Govekar, R. B., Patil, A., Kane, S. V., Chaturvedi, P., D'Cruz, A. K. and Zingde, S. M. (2013), Prognostic utility of autoantibodies to α-enolase and Hsp70 for cancer of the gingivo-buccal complex using immunoproteomics. Prot. Clin. Appl., 7: 392–402. doi: 10.1002/prca.201200081
- Issue published online: 18 JUN 2013
- Article first published online: 1 MAR 2013
- Accepted manuscript online: 17 NOV 2012 05:54AM EST
- Manuscript Accepted: 26 OCT 2012
- Manuscript Revised: 11 OCT 2012
- Manuscript Received: 9 AUG 2012
- Council of Scientific and Industrial Research. Grant Number: 27(0151)/06/EMR-II
- Lady Tata Memorial Trust
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Figures S1 (A–L) ; Representative autographs of 2DE blots of KB lysates probed with IgG purified from sera of patients with cancer of GBC and normal healthy individuals. Position of the signals for alpha enolase a, b and c (marked a, b, c), Hsp 70 and some of the other antigens are shown with red arrows. The same signals are not found in autographs probed with IgG from sera of normal healthy controls as shown in Fig. (K, L). The numbers written on the top left are the sample numbers of the patients with cancer of GBC. CL22 and CL 45 are the blots for the control samples.
Figures S2 (A–J); Kaplan-Meier curves with univariate analysis for correlation of cumulative survival and DFS (in months) with autoantibody response in groups of patients negative for autoantibody response to each of the antigens shown and those positive for the response. A) Peroxiredoxin 6 (Prdx 6); B) Annexin 2 (Anx 2); C) ATP synthase (Atps); D) Pyruvate kinase (PKm); E) alpha tubulin (α tub); and F) beta tubulin (ß tub); G) aldose keto reductase 1 (AR 1); H) aldose keto reductase 2 (AR 2); I) phosphoglycerate mutase (Pgm); J) TPI. The number of patients in each group is given as (N) against each curve
Figure S3. Kaplan-Meier curves for correlation of cumulative survival and DFS (in months) in A) patients with and without nodal involvement, (node +ve and node –ve; B) patients with WD, moderately differentiated (MD) and poorly differentiated (PD) tumors. The number of patients in each group is given as (N) against each curve.
Table S1: Clinical information and autoantibody response to tumor antigens in patients with cancer of GBC
Table S2: Clinical information and autoantibody response to tumor antigens in healthy individuals
Table S3: Autoantibody response to identified tumor antigens in patients with cancer of GBC and normal healthy individuals.
Table S4: Correlation of autoantibody response to ɑ enolase and Hsp70 with clinicopathological parameters in patients with GBC cancer
Table S5: Correlation of autoantibody response to other tumor antigens with clinicopathological parameters of patients with cancer of GBC
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.